Population pharmacokinetics of meropenem among post-operative patients in Pakistan

Abstract

Insights

Meropenem clearance is primarily affected by kidney function. This study developed a population pharmacokinetic model to optimize meropenem dosing based on patient creatinine clearance (CRCL) for improved treatment outcomes.

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Clinical Pharmacology
  • Infectious Diseases

Background:

  • Meropenem is a critical carbapenem antibiotic for severe infections.
  • As a hydrophilic drug, meropenem is predominantly renally excreted (>83%).
  • Patient kidney status significantly impacts meropenem clearance (CL).

Purpose of the Study:

  • To develop a population pharmacokinetic (popPK) model for meropenem.
  • To investigate the influence of covariates (age, body weight, CRCL, gender) on meropenem CL.
  • To simulate optimal meropenem dosing regimens based on renal status.

Main Methods:

  • Utilized data from 59 patients (205 samples) treated with meropenem.
  • Employed nonlinear mixed-effects modeling for popPK analysis.
  • Applied stepwise covariate modeling and simulations for dosage regimen evaluation.

Main Results:

  • A two-compartment model best described meropenem pharmacokinetics.
  • Creatinine clearance (CRCL) was the sole significant covariate affecting meropenem CL.
  • Simulated regimens showed comparable efficacy below CRCL ≤ 100 mL/min; 1000 mg q8h was superior above CRCL > 100 mL/min.

Conclusions:

  • Meropenem CL is significantly dependent on patient renal function (CRCL).
  • The developed popPK model enables tailored meropenem dosing based on CRCL.
  • This approach can optimize meropenem therapy in Pakistani patients.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
108
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
130
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
59
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
104
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
111